Pei Lin et al. assert that the only Myc aberration, in unclassifiable B-cell lymphoma, identifies patient subsets, requiring more aggressive therapy than R-CHOP [58]. The gene discussed is MYC; the disease is B-cell non-Hodgkin lymphoma.